WebRudolph et al, 16 in a recent study, found that concurrent immunomodulators enhance maintenance of response to infliximab, particularly if started more than 3 months before the initiation of ... WebObjectives: To assess the efficacy of infliximab in sarcoidosis. Methods: A phase 2, multicenter, randomized, double-blind, placebo …
Infliximab Therapy in Patients with Chronic Sarcoidosis and …
WebDurability of infliximab dosing for patients with “extensive” disease. Since initiation of IFX, patients were studied for a mean of 28 ± 16.2 months (range 6.2–64.7 months). Survival … WebBackground Infliximab (IFX) discontinuation is not uncommon during the first year of treatment due to inadequate drug concentrations and anti-IFX antibodies (ATI). Both combination therapy and proactive therapeutic drug monitoring (pTDM) are used to decrease ATI and increase IFX durability. marion county record newspaper kansas
Long-term durability and dose escalation patterns in infliximab …
WebThe difference in time to discontinuation at 52 months of follow-up between the infliximab and adalimumab subgroups, as either first- or second-line treatment, was not statistically … WebWe evaluated LOR to biologics in our Crohn disease (CD) patients receiving biologics. Of 137 biologic-treated CD patients, 68 continuously receiving the same biologic type for at … WebFeb 24, 2015 · Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn’s disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug … marion county records department